The Drug Enforcement Administration (DEA), a government agency that prides itself on protecting the American people from harmful substances, has recently come under fire for its contradictory actions. On one hand, it is actively hindering a legitimate pharmaceutical company from developing cannabis-based medications that comply with federal regulations. On the other hand, it has openly admitted its inability to effectively shut down illegal cartel operations in states where cannabis has been legalized. Talk about a double standard, am I right?
Let’s break this down, shall we? The DEA, which falls under the jurisdiction of the Department of Justice, was established in 1973 with the noble mission of enforcing federal drug laws and combating drug trafficking. However, in recent years, its focus has shifted towards the ever-controversial topic of cannabis. While some states have legalized the use of marijuana for medicinal and/or recreational purposes, it remains a Schedule I drug at the federal level, meaning it is considered to have no accepted medical use and a high potential for abuse.
Enter the pharmaceutical company, which shall remain nameless for the sake of anonymity. This company has been diligently working towards developing cannabis-based medications that comply with federal regulations. They have jumped through all the necessary hoops, obtained all the required permits, and have even received approval from the Food and Drug Administration (FDA) to conduct clinical trials. Sounds like a promising step towards providing patients with safe and effective cannabis treatments, right? Wrong.
The DEA, in all its bureaucratic glory, has thrown a wrench in the company’s plans by refusing to grant them a license to grow cannabis for research purposes. This is despite the fact that the company has met all the criteria set forth by the DEA and has even secured a partnership with a university to conduct the research. So why the roadblock? Well, according to the DEA, there is only one federally-approved source for cannabis used in research, and that is the University of Mississippi. Yes, you read that correctly. The same university that has been supplying subpar cannabis for research purposes since 1968. Talk about a monopoly.
But wait, it gets even more absurd. While the
